Gene mutation may lead to treatment for liver cancer
Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to new research.
A team led by the Icahn School of Medicine at Mount Sinai in New York, New York, and Harvard Medical School in Boston, Massachusetts, has discovered a link between the presence of two mutant proteins, IDH1 and IDH2, and cancer. Past studies have found IDH mutations to be among the most common genetic differences seen in patients with iCCA, but how they contribute to cancer development was unknown going into the current effort.
iCCA strikes bile ducts, tube-like structures in the liver that carry bile, which is required for the digestion of food. With so much still unknown about the disease, there is no first-line, standard of care and no successful therapies.
"iCCA is resistant to standard treatments like chemotherapy and radiation," said Josep Maria Llovet, MD, Director of the Liver Cancer Program, Division of Medicine, Icahn School of Medicine at Mount Sinai, and a contributing author. The study was published in Nature (2014; doi:10.1038/nature13441). "Understanding the molecular mechanism of the disease is the key to finding a treatment that works."
Llovet and colleagues demonstrated that the expression of mutant IDH in the adult liver of genetically engineered mice impairs liver cell development and liver regeneration—a process in which the liver responds to injury, and it increases the number of cells to form a tumor. Moreover, mutant IDH were found to work with activated KRAS, a gene essential in cancer development, causing the development of premalignant lesions and a progression to metastatic iCCA.
"Our findings provide novel insights into the development iCCA and offers a possible treatment option for patients suffering from this fatal disease," said Llovet.
By pinpointing one pathway of iCCA, this study opens up a new line of investigation to identify biomarkers of the disease. Already, phase 1 clinical trials are being conducted with specific IDH1/2 mutations. The hope is that results of these and future studies can help doctors make life-saving decisions for their patients.